Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

A modular IgG-scFv bispecific antibody topology.

Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, Wittrup KD.

Protein Eng Des Sel. 2010 Apr;23(4):221-8. doi: 10.1093/protein/gzp077. Epub 2009 Dec 17.

2.

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Schanzer JM, Wartha K, Croasdale R, Moser S, K√ľnkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, Stracke J, Lau W, Ries S, Brinkmann U, Klein C, Umana P.

J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19.

3.

Fab-based bispecific antibody formats with robust biophysical properties and biological activity.

Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, Glasebrook AL, Kuhlman B, Demarest SJ.

MAbs. 2015;7(3):470-82. doi: 10.1080/19420862.2015.1022694.

4.

Nanocell targeting using engineered bispecific antibodies.

Taylor K, Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H, Munro TP, Mahler SM.

MAbs. 2015;7(1):53-65. doi: 10.4161/19420862.2014.985952.

5.

Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.

Shen J, Vil MD, Jimenez X, Iacolina M, Zhang H, Zhu Z.

J Biol Chem. 2006 Apr 21;281(16):10706-14. Epub 2006 Feb 15.

6.

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, Garber E, Browning J, Glaser SM.

MAbs. 2009 Mar-Apr;1(2):128-41. Epub 2009 Mar 11.

7.

Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.

Asano R, Shimomura I, Konno S, Ito A, Masakari Y, Orimo R, Taki S, Arai K, Ogata H, Okada M, Furumoto S, Onitsuka M, Omasa T, Hayashi H, Katayose Y, Unno M, Kudo T, Umetsu M, Kumagai I.

MAbs. 2014;6(5):1243-54. doi: 10.4161/mabs.29445. Epub 2014 Oct 30.

8.

Stability engineering of scFvs for the development of bispecific and multivalent antibodies.

Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, Glaser SM.

Protein Eng Des Sel. 2010 Jul;23(7):549-57. doi: 10.1093/protein/gzq028. Epub 2010 May 10.

PMID:
20457695
9.

Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.

Shen J, Vil MD, Jimenez X, Zhang H, Iacolina M, Mangalampalli V, Balderes P, Ludwig DL, Zhu Z.

J Immunol Methods. 2007 Jan 10;318(1-2):65-74. Epub 2006 Oct 26.

PMID:
17126853
10.

An efficient route to the production of an IgG-like bispecific antibody.

Zuo Z, Jimenez X, Witte L, Zhu Z.

Protein Eng. 2000 May;13(5):361-7.

PMID:
10835110
11.

Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.

Vendel MC, Favis M, Snyder WB, Huang F, Capili AD, Dong J, Glaser SM, Miller BR, Demarest SJ.

Arch Biochem Biophys. 2012 Oct 15;526(2):188-93. doi: 10.1016/j.abb.2011.12.018. Epub 2012 Jan 2.

PMID:
22230329
12.

Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.

Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, Bossenmaier B, Umana P, Sustmann C, Brinkmann U.

Protein Eng Des Sel. 2012 Oct;25(10):571-80. Epub 2012 Sep 13.

13.

Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.

Lu D, Zhu Z.

Methods Mol Biol. 2014;1060:185-213. doi: 10.1007/978-1-62703-586-6_11.

PMID:
24037843
14.

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, Jaeger C, Ferrara C, Hoffmann E, Kling L, Lau W, Staack RF, Heinrich J, Scheuer W, Stracke J, Gerdes C, Brinkmann U, Umana P, Klein C.

Arch Biochem Biophys. 2012 Oct 15;526(2):206-18. doi: 10.1016/j.abb.2012.03.016. Epub 2012 Mar 21.

PMID:
22464987
15.

Bispecific antibody derivatives based on full-length IgG formats.

Grote M, Haas AK, Klein C, Schaefer W, Brinkmann U.

Methods Mol Biol. 2012;901:247-63. doi: 10.1007/978-1-61779-931-0_16.

PMID:
22723106
16.

Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.

Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I.

J Biol Chem. 2007 Sep 21;282(38):27659-65. Epub 2007 Jul 19.

17.

Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.

Cheng M, Ahmed M, Xu H, Cheung NK.

Int J Cancer. 2015 Jan 15;136(2):476-86. doi: 10.1002/ijc.29007. Epub 2014 Jun 19.

18.

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM.

Mol Immunol. 1999 May;36(7):433-45.

PMID:
10449096
19.

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.

Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, Hansen-Estruch C, Chamberlain AK, Truhlar SM, Conner EM, Atwell S, Kuhlman B, Demarest SJ.

Nat Biotechnol. 2014 Feb;32(2):191-8. doi: 10.1038/nbt.2797. Epub 2014 Jan 26.

PMID:
24463572
20.

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.

Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, Sutton J, Chaparro-Riggers J, Chen W, Casas MG, Chin SM, Wong OK, Liu SH, Vergara G, Shelton D, Rajpal A, Pons J.

J Mol Biol. 2012 Jul 13;420(3):204-19. doi: 10.1016/j.jmb.2012.04.020. Epub 2012 Apr 25.

PMID:
22543237

Supplemental Content

Support Center